Structured evidence table for Beta Glucan Gut Microbiome Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Beta Glucan Gut Microbiome Randomized Trial | Owing to the limited number of human and mechanistic studies, we recommend a multidisciplinary approach integrating expertise in food processing, analytical chemistry, and microbiology to further elucidate their potential to improve health through gut microbiome modulation. | 3 | Keigler Johanna I. (2026) | Myco-foods and the gut microbiome: impacts of mycelial extracts, biomass, and mold-fermented foods |
| Beta Glucan Gut Microbiome Randomized Trial | Specifically, a longitudinal study examined for changes to the gut microbiota and metabolites of 15 healthy subjects who consumed 4.5 g CG daily for three weeks.The intake of CG was associated with changes in the relative abundance of nine microbial genera, including significant increases in, andand decreases inandIncreases in the fecal levels of the SCFAs butyric, caproic, and isovaleric acids were also reported. | 3 | Keigler Johanna I. (2026) | Myco-foods and the gut microbiome: impacts of mycelial extracts, biomass, and mold-fermented foods |
| Beta Glucan Gut Microbiome Randomized Trial | Supplementation with H(via water) was associated with improved glucose and lipid metabolism in a clinical trial.Thus, hydrogen production may be one mechanism through which fungal fiber fermentation by the gut microbiota influences host metabolism. | 3 | Keigler Johanna I. (2026) | Myco-foods and the gut microbiome: impacts of mycelial extracts, biomass, and mold-fermented foods |
| Beta Glucan Gut Microbiome Randomized Trial | Many compounds with medicinal importance (such as antibiotics, immunosuppressants, and statins) have been extracted or derived from molds, includingandspecies.However, mycelial extracts from edible molds are also of interest because of their high fiber and other bioactive contents. | 3 | Keigler Johanna I. (2026) | Myco-foods and the gut microbiome: impacts of mycelial extracts, biomass, and mold-fermented foods |
| Beta Glucan Gut Microbiome Randomized Trial | Preclinical and emerging clinical evidence supports broad therapeutic potential across multiple disease domains, including inflammatory bowel disease, metabolic disorders, respiratory infections, and cancer. | 4 | Samiksha F (2026) | Fungal β-1,3-glucans: Cell Wall Constituents That Promote Gut Health Through Innate Immune Modulation. |
| Beta Glucan Gut Microbiome Randomized Trial | Fungal β-1,3-glucans are structurally conserved polysaccharide components of the fungal cell wall that exhibit potent immunomodulatory activity. | 4 | Samiksha F (2026) | Fungal β-1,3-glucans: Cell Wall Constituents That Promote Gut Health Through Innate Immune Modulation. |
| Beta Glucan Gut Microbiome Randomized Trial | These molecules are recognized by pattern recognition receptors, Toll-like receptors, complement receptor 3, lactosylceramide, scavenger receptors, and EphA2. | 4 | Samiksha F (2026) | Fungal β-1,3-glucans: Cell Wall Constituents That Promote Gut Health Through Innate Immune Modulation. |
Source documents